SLC5A2 and type 2 diabetes mellitus: This is important given that SGLT-2 inhibitors such as canagliflozin effectively reduce epicardial fat (Yagi et al., 2017) and empagliflozin improved glucose control and has been demonstrated to reduce cardiovascular events in T2DM (Zinman et al., 2015).